Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of SGLT-2 Inhibition With Dapagliflozin on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI With T1- and T2-mapping in Patients With Type-2 Diabetes

NCT03782259 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03782259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03782259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of SGLT-2 Inhibition With Dapagliflozin on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI With T1- and T2-mapping in Patients With Type-2 Diabetes
Lead sponsor
University of Washington
Phase
Phase 4
Overall status
Completed
Start date
February 26, 2019
Completion date
November 16, 2022
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myocardial fibrosis, myocardial inflammation, type 2 diabetes mellitus